10.50% p.a. JB Multi Barrier Reverse Convertible (70% European) with Lock-In on Eli Lilly & Co, Roche Holding AG, Novo Nordisk A/S
-
Valor
132871800
-
ISIN
CH1328718007
-
Symbol
MCAGJB
- SVSP Category Yield enhancement
- SVSP Type Barrier Reverse Convertibles
- SVSP Code 1230
Bid
%Volume:
Ask
%Volume:
Price
as of:Distance to strike (%) | -57.05% |
Distance to barrier | -9.94% |
Delta | LLY=0.152,NVO=0.632,ROG=0.034 |
multiple Underlyings | Yes | |||||||
days to maturity | 250 | |||||||
Summary Risk Indicator (SRI)* |
|
*All statements without guarantee.
JB ESG Category | Responsible Investments |
SFDR Alignment (JB View) | No |
EU Taxonomy Aligned | No |
% of EU Taxonomy Alignment | 0.00% |
Daily high (bid) | 78.75 |
Daily low (bid) | 73.80 |
52 Week high (bid) | 98.60 |
52 Week low (bid) | 73.80 |
Alltime high (bid) | 98.60 |
Alltime low (bid) | 73.80 |
Worst performing underlying | Novo Nordisk |
Performance of the underlying since issue | -36.33% |
Initial fixing date | 20/09/2024 |
Issue date | 27/09/2024 |
Next coupon payment | 27/01/2025 |
Maturity date | 22/09/2025 |
Callability | No |
Issuer | Bank Julius Baer & Co. Ltd., Guernsey |
Underlying |
Eli Lilly & Co Novo Nordisk Roche Holding Ltd |
Issue price | 100.00 |
Currency | USD |
Listing | Yes |
COSI | No |
Coupon p.a. | 10.50% |
Strike | 100% |
Barrier (%) | 70.00% |
Barrier observation | continuous |
Quanto | Yes |
Trigger Barrier | 105.00% |
Trigger Step-Down | No |
Payment Scenario Barrier Reverse Convertibles
market expectation
characteristics
- Underlying moving sideways or slightly rising
- Falling volatility
- Underlying will not breach barrierduring product lifetime
- Should the barrier never be breached, the nominal plus coupon is paid at redemption
- Due to the barrier, the probability of maximum redemption is higher; the coupon, however, is smaller than for a Reverse Convertible
- If the barrier is breached the product changes into a Reverse Convertible
- The coupon is paid regardless of the underlying development
- Reduced risk compared to a direct investment into the underlying
- With higher risk levels, multiple underlyings (“Worst-of”) allow for higher coupons or lower barriers
- Limited profit opportunity(cap)
Eli Lilly & Co
- Ticker SymbolLLY UN
- Valor947556
- ISINUS5324571083
746.44 USD
Novo Nordisk
- Ticker SymbolNVO UN
- Valor461641
- ISINUS6701002056
81.48 USD
Roche Holding Ltd
- Ticker SymbolROG SW
- Valor1203204
- ISINCH0012032048
263.40 CHF
Underlying | Valor | ISIN | Price | Strike | Barrier absolute | Ratio |
---|---|---|---|---|---|---|
Eli Lilly & Co | 947556 | US5324571083 | -6.70% | 921.49 | 645.043 | |
Novo Nordisk | 461641 | US6701002056 | +0.00% | 127.51 | 89.257 | |
Roche Holding Ltd | 1203204 | CH0012032048 | -0.57% | 269.2 | 188.44 |